MMED Company Profile and Key Details

Average 10-day trading volume of 889.12 thousand shares is in line with the 3-month average of 929.29 thousand, indicating normal recent market interest.

Analyst sentiment is bullish. Analyst rating data shows there are 6 Strong Buy ratings, 5 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $27.00 to $16.00. The high target offers 67.7% upside. The low target suggests -0.62% downside. The mean target is $22.08. This offers 37.14% upside. MiniMed Group, Inc. Common Stock earnings surprise history is a mixed track record. The quarter that ended June 03, 2026, missed forecasts by 356.16%. The prior quarter beat by 17.51%. Over the last six quarters, Apple has recorded several small beats. These include 17.51% in April 17, 2026.

MiniMed Group, Inc. Common Stock last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $44.83. This means the shares are trading below this model’s fair value.

MiniMed Group, Inc. Common Stock (NASDAQ:MMED) closed at $16.10 USD, gaining $0.81 (5.30%) from the previous close of $15.29. The stock is currently mid-range between its 52-week high and low $10.65 and $20.48. With a market capitalization of about $4.52 billion, MiniMed Group, Inc. Common Stock is classified as a mid-cap and shows lower-than-market volatility (beta ~-3.63). Key stats such as the average daily volume over the past year has been around 921.35 thousand shares, trading with heavier-than-usual volume. Headquartered in Northridge, CA, MiniMed Group, Inc. Common Stock operates in the Healthcare sector and the Medical - Equipment & Services industry. Led by CEO Que Thanh Dallara, the company employs approximately 8,000 people and listed since March 05, 2026. MiniMed Group, Inc. specializes in designing, producing, and distributing a broad spectrum of medical technologies and solutions aimed at effective diabetes management.

Valuation shows MiniMed Group, Inc. Common Stock trading at a premium to the broader market with a P/E of -14.43. Analyst sentiment is bullish, with the majority of ratings in Overweight territory and a mean price target of $22.08, suggesting 37.14% upside. Our AI forecast model points to short-term strength (0.75% over two weeks), a medium-term fall (-97.64% over three months), and a longer-term gain (1662.73% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that MiniMed Group, Inc. Common Stock stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 0.75%, with price expected at $16.22 by July 27, 2026, within a range of $15.43 to $17.05 3-Month Outlook: Projected fall of -97.64%, reaching $0.38 by October 08, 2026, with a range of $0.27 to $0.51. 1-Year Outlook: Projected gain of 1662.73%, with price at $283.80 by July 13, 2027, within a range of $283.63 to $283.93.

MiniMed Group, Inc. Common Stock trades at a P/E ratio of -14.43, slightly below the S&P 500 average, with a price-to-sales ratio of 1.9 and a price-to-book ratio of 1.18 suggesting the stock is closer to book value. The P/FCF stands at -23.83, also below market averages.